U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07653126) titled 'A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany' on June 12.
Brief Summary: The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
Study Start Date: April 03, 2023
Study Type: OBSERVATIONAL
Condition:
Gastro-enteropancreatic Neuroendocrine Tumor
Recruitment Status: COMPLETED
Sponsor: Novartis Pharmaceuticals
Disclaimer: Curated by HT Syndication....